イスタンブールで最高のPET-CT検査医師 - トップ42名の医師

ムスタファ・ソラック博士（M.D.）は 1978年に生まれ、ハジェッテペ大学の医学部を卒業しました。彼はイスタンブールのシシュリエトファール教育研究病院で研修を修了し、ハジェッテペ大学がん研究所でフェローシップを完了しました。

彼は多くの乳がん、精巣がん、卵巣がん、肺がん、頭頸部がん、消化器がんの症例を担当してきました。

医療分野の関心領域

乳がん

精巣がん

卵巣がん

肺がん

頭頸部がん

消化器がん

学歴:

学士: ハジェッテペ大学医学部

専門分野: イスタンブール・シシュリエトファール教育研究病院

副専門分野: ハジェッテペ大学がん研究所

教育および勤務した施設

テキサス大学 MD アンダーソンがんセンター

ヒティット大学コルム教育病院

メディカルパーク病院

核医学専門医

ブルント・カラゲズ博士は、トルコのトップ医療腫瘍学者であり、肉腫、リンパ腫、膵臓、肺がんの専門家であり、乳がん外科の医師で、20年以上の経験を持ちます。彼の主なサブスペシャリティは、腫瘍生物学、腫瘍免疫学、がん免疫療法、標的療法です。

職務経験

• 2019年から — アナドル医療センターの医療腫瘍学者
• 2019年 — イスタンブールオカン大学医学部の内科部長、内科および医療腫瘍学部門の部門長および医学倫理委員会の委員長
• 2017-2019年 — GATA ハイダルパシャトレーニング病院の内科の医療腫瘍学部門の部門長
• 2012-2017年 — GATA ハイダルパシャトレーニング病院の内科の医療腫瘍学部セクションの責任者
• 2003年 — チョルル兵士病院の内科医
• 2001年 — NATO の NATO KFOR コマンド
• 1993-1995年 — トルコ系キプロス和平部隊の司令部。

教育

• 1992年 — ギュルハネ軍医科大学 — 一般医学の学位
• 1999年 — GATA ハイダルパシャトレーニング病院 — 内科の専門
• 2006年 — GATA ハイダルパシャトレーニング病院 — 医療腫瘍学の専門。

教育活動

• 2017年 — イスタンブールオカン大学医学部の教授。

科学活動

がん研究で40を超える出版物を執筆しています。

会員資格

• トルコ医療腫瘍学協会

ヨーロッパ頭頸部協会

コース参加

• 腫瘍生物学コース、医療腫瘍学協会、2003年。
• フローサイトメトリートレーニング、イスタンブール大学 (DETAE)、2004年。
• 基本的な疫学（健康における研究手法と分析技術）コース、GATA コマンド、2005年。
• 臨床研究における倫理的アプローチコース、厚生労働省医薬品局および薬局の総局、2009年および2017年（2回）。

エダ・タンルクリ博士はアナドル・メディカルセンターにおけるがんのトップ腫瘍専門医の一人で、医学的腫瘍学と化学療法に専門知識を持っています。 

教育

• 2005年 - アンカラ大学医学部、医師、アンカラ
• 2012年 - イスタンブール大学、ジェッラパシャ医学部、内科専門医、イスタンブール
• 2017年 - マルマラ大学、医学部、医学腫瘍専門医、イスタンブール

2005年にアンカラ大学医学部を卒業後、彼女は2006年にカルスで必修サービスを完了しました。2007年から2012年にかけてイスタンブール大学ジェッラパシャ医学部で内科の専門研修を完了しました。彼女は2013年にトルコで実施された小専門医試験で3位になり、マルマラ大学医学部の医学腫瘍学科で医学腫瘍学の研修を開始しました。2017年に医学腫瘍の専門研修を完了し、2018年から2021年までハイダルパシャ ヌミュ内科および腫瘍ユニットの責任者として勤務しました。医学腫瘍の分野で多くの国際臨床研究で助手および主任研究者として勤務したタンルクリ・シムシェクは、2021年12月からアナドル・メディカルセンターで医学腫瘍医として勤務を開始しました。 

専門

• 乳癌
• 泌尿器系がん
• 肺癌
• 大腸および直腸がん
• 胃がん
• 膵臓がん
• 食道がん
• 婦人科系がん
• 悪性黒色腫
• 軟部肉腫および骨肉腫
• 個別化治療
  
  受賞歴
  2013年 トルコ血液学会 血液学論文賞
  
  所属機関
  
  トルコ医学腫瘍学会 (TTOD)
• ヨーロッパ医学腫瘍学会(ESMO)
• アメリカ医学腫瘍学会(ASCO)
  
  コース参加
  
  トルコ・中国協力プロジェクト、大腸がん交換プログラム、上海、中国。2014年
• オックスフォード大学、ラドクリフ医学部、転移性大腸がん実習、オックスフォード、イギリス、2015年
• クリスティー肺癌実習- ESMO、マンチェスター、イギリス、2016年
• 欧州黒色腫経験交流：治療に焦点を当てて、エッセン、ドイツ（オンライン）、2020年

イルケル・ティナイ医師は、アナドール医療センターで、低侵襲手術、ネオ膀胱再建手術、泌尿器がんのエキスパートである泌尿器科腫瘍専門医です。彼は英語とドイツ語を話し、イスタンブール大学で学士号を取得し、マルマラ大学で泌尿器科のレジデンシーを完了しました。
 

• 泌尿器がん腫瘍学
• 低侵襲手術
• ネオ膀胱再建
• 泌尿器がん
• 英語とドイツ語
• イスタンブール大学の学士号
• マルマラ大学の泌尿器科学レジデンシー
• Urooncology協会理事会の執行役員
• Urooncology協会膀胱腫瘍研究グループの書記
• 泌尿器科手術協会北マルマラ支部の理事会メンバー
• 国際膀胱がんネットワーク
• 欧州泌尿器科学会のメンバー
• アメリカ外科医カレッジのメンバー
  Aquablationセラピー
  
  専門分野
• 泌尿器がん腫瘍学
• 低侵襲手術
• 泌尿器がんバイオマーカー
  
  受賞歴
  
  マルマラ大学医学部住居医学生科学奨励賞、2008年
•  
• 国立泌尿器科手術会議、若手学術発表賞、2012年

Urooncology協会科学研究賞、2019年

Urooncology協会理事会 メンバー

機関会員

Urooncology協会膀胱腫瘍研究グループ 書記

• 泌尿器科手術協会北マルマラ支部の理事会メンバー
• 国際膀胱がんネットワーク
• 欧州泌尿器科学会のメンバー
• アメリカ外科医カレッジのメンバー

キヴァンチ・デリヤ・ペケル教授は、イスタンブール大学イスタンブール医学部（チャパ）で医学教育と一般外科専門医の教育を修了しました。主要なスペシャリゼーションの後、カルトル・コシュユオルゥ・ユクセック・イフティーサス教育・研究病院の消化器外科クリニックで消化器外科専門医資格を取得しました。

サブブランチのアシスタントシップ中に、トルコ外科協会から奨学金を受け、メイヨークリニック（ロチェスター、米国）の肝胆膵外科クリニックおよび肥満・代謝外科クリニックで働きました。トルコに帰国後、バクルキョイ・ドクター・サディ・コヌク教育研究病院で肝胆膵外科ユニットの創設者の一人となりました。この病院はトルコHPB協会から訓練ユニットとして認められ、一般外科レジデントや消化器外科レジデントには肝胆膵外科のトレーニングを提供しました。

一方で、幹細胞、癌生物学、肥満と老化の細胞性特性を学ぶため、イスタンブール大学イスタンブール医学部（チャパ）の医学生物学部で老化に関する博士号を取得し、論文を書きました。その後、消化器外科クリニックを設立するため、バシャクシェヒル・チャム・サクラシティ病院に移動しました。

特にキャリアにおいて、膵臓疾患と外科、胆嚢と胆管疾患の外科、肝臓がんの外科、胃がんの外科、肥満・代謝外科に興味を持っています。ペケルは多くの成功した手術を行いました。これまでに400件以上の膵臓および胃がんの手術、200件以上の肝臓手術、胆嚢と胆管疾患に関する多くの手術、肥満 – 代謝外科および内視鏡治療、腎臓移植を行ってきました。また、老化と幹細胞治療にも関心があります。

医学的興味

• 膵臓外科
• 胆嚢と胆管の外科
• 肝疾患の外科
• 肥満 – 代謝外科および内視鏡治療

Assoc. Prof. Dr. Tamer Aksoy graduated from Eskişehir Osmangazi University in 2000. After working as a Management Representative at SSK Tavşanlı Hospital, he worked as a General Practitioner at SSK Ankara Etlik Specialization Hospital Endocrinology Department and started his residency training at Hacettepe University Nuclear Medicine Department in 2005 and completed his specialization in 2009 and became a Nuclear Medicine specialist.

After working as an Assistant Professor at Afyon Kocatepe University Faculty of Medicine, Department of Nuclear Medicine, he started to work at Haydarpaşa Numune Training and Research Hospital in 2011. In 2012, Aksoy worked as an Assistant Professor at Acıbadem Hospitals group and Acıbadem Mehmet Ali Aydınlar University Faculty of Medicine. Dr. Aksoy, who worked as a Lecturer at Acıbadem Hospitals group and Acıbadem Mehmet Ali Aydınlar University Faculty of Medicine in 2012, started to work at Health Sciences University Istanbul Training and Research Hospital Nuclear Medicine Clinic in 2018 and ended his duty in 2023.

In 2012, he worked as a clinical researcher at the Netherlands Cancer Institute - Antoni van Leeuwenhoek (NKI) Hospital (Amsterdam / Netherlands) Nuclear Medicine Clinic (Netherlands) as an observer on PET imaging, Lymphoscintigraphy and Radionuclide Therapies. In February 2023, he received the title of Associate Professor. He has been serving his patients at Hisar Hospital Intercontinental since May 2023.

During his professional life, he has been accepting and following up patients especially on PET/CT examinations and Radionuclide Therapies.

He is a member of Turkish Medical Association, Turkish Nuclear Medicine Association and European Nuclear Medicine Association.

MEDICAL AREAS OF INTEREST

Pet-BT

Radionuclide Therapy

Dr. Sertkaya graduated from Konya Meram Science High School in 2001 and entered Gazi University Medical Faculty the same year, graduating in 2008. He completed his urology specialization at Haydarpaşa Numune Training and Research Hospital in 2014, becoming a urology specialist.

Since becoming a specialist, he has focused on the sub-branch of Andrology, attending various training sessions and conferences and performing surgeries with some of the world's leading Andrology professors. In 2017, he passed the written and oral proficiency exams conducted by the European Association of Urology, earning the title of "FEBU."

In 2020, Dr. Sertkaya achieved the rank of Associate Professor of Urology. His journey in Urology and Andrology, which began in 2008, continues at the Andro Expertise Male Health and Aesthetics Center, which he founded in 2022. He sees patients in his own clinic and performs surgeries at affiliated hospitals.

学歴、受賞歴および資格証明

• 学校間プロジェクトコンクール、トルコ全国第3位、廃バッテリーから得られた活性炭のイオン・ガス吸着材としての利用、トルコ科学技術研究評議会（TUBİTAK）－2009年

• トカット理数科高等学校 – 2010年

• イスタンブール大学医学部（優等卒業） – 2016年

• サルイェル公立病院（救急医療）、2017年

• 動物実験認定証 – 2019年1月

• マイクロサージャリー認定証 – 2019年5月

• 医療統計認定証 – 2019年7月

• バーチュラル研究・教育病院、形成外科・再建外科・

美容外科（専門医研修）2017年－2022年

• ウニベルシタ・カンパス・ビオ・メディコ、形成外科・再建外科・美容外科講座

ローマ／イタリア（マイクロサージャリー奨学研修）2022年－

• エルズルム公立病院、エルズルム／トルコ、2022年－2024年

メディポル・アジバデム地区病院（現職）

Dr. Gokhan Yilmaz is an experienced general surgeon with nearly 20 years in medical practice. He is known for his skill in complex surgical procedures. He earned his Master’s Degree from Istanbul University Çapa Faculty of Medicine. He completed his Doctorate in General Surgery at Okmeydanı Training and Research Hospital, one of Turkey’s leading institutions.

Dr. Yilmaz worked as a General Surgery Specialist at Zonguldak Atatürk State Hospital for 5 years. He then served at Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital for 3 years. In these roles, he managed a wide range of surgical cases. He also served as an Assistant Professor at Istanbul Medipol University, where he trained future surgeons and contributed to research.

Dr. Yilmaz is currently part of the General Surgery Department at Medipol University Pendik Hospital. He provides advanced treatments and high-quality patient care. His experience in state hospitals, research centers, and universities highlights his dedication to surgical excellence and patient safety.

Personal Information 

Sex:  Male

Born : 1968 

Professional Experience

Gayrettepe Florence Nigthingale Hospital

Medical Oncology Department

Besiktas/Istanbul/Turkey (ongoing)

Education:

He became Professor (22/April /2016)

Medical Oncology

Attending Phys.in Gastrointestinal Oncology (January 2005 ,2009)

Istanbul University Oncology Institue,

Department of Medical Oncology

Medical Oncology Fellowship (December 2001-December2004)

Istanbul University, Istanbul Medical Faculty

Hemodialysis Traning (May1996-January1997)

Istanbul University ,bCerrahpasa Medical Faculty

Internal Medicine Residency (November 1991-November 1996)

Istanbul University ,bCerrahpasa Medical Faculty

Ege University Medical Faculty (1985-1991)

Professional Experience

February 1999-November 2001

Metropolitan Florence Nigthingale Hospital

American Cancer Center, Gayrettepe/İstanbul

April1997- October 1998

Bayraktar Dialysis Center

Güngören/ Istanbul

Membership

Turkish Medical Oncology Association

ENET(European Neuroendocrine Tumour Society)

ESMO

ASCO

Personal information

Title: Professor Doctor

Branch: Radiation Oncology

Work History:

1 GATA Military Medical Faculty

2 Gayrettepe Florence Nightingale Hospital

3 T.R. Demiroğlu Bilim University \ Associate Professor

4 T.R Demiroğlu Bilim University \ Professor

Medical Specialties and Subspecialties:

1 Head and Neck Cancers

2 Radiation Oncology

Priority treatments:

1 Prostate cancer

2 Conformal treatments

Special advanced health technologies:

1 Truebeam Stx Technology

2 Halcyons

Education

1991 - Istanbul University Istanbul Faculty of Medicine

1996 - Istanbul University Cerrahpaşa Faculty of Medicine Radiation

Oncology Specialization Training

Experience

2022 PRIVATE MEDIPOL BAHÇELİEVLER HOSPITAL

2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital, Medical Oncology Clinic Education Officer

2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital

2020 - 2021 Yüzüncü Yıl University Faculty of Medicine

2020 - 2021 Head of the Department of Medical Oncology, Yüzüncü Yıl University Faculty of Medicine, Assoc. Dr.  

2018 - 2021 Lecturer - Yüzüncü Yıl University Faculty of Medicine, Head of Medical Oncology Department  

2018 - 2021 Yüzüncü Yıl University Faculty of Medicine

2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital

2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital, Medical Oncology Clinic, Sub-branch assistant

2012 - 2015 Kanuni Sultan Süleyman Training and Research Hospital, Internal Medicine specialist

2012 - 2015 Suleiman the Magnificent Training and Research Hospital,

2008 - 2012 Haseki Training and Research Hospital

2006 - 2008 Kızıltepe No. 3 Health Center General Practitioner.

Education

2018

İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

2018

İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji, İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

2012

İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları, İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

2012

İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

2007

Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi, Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi

Experience:

2022 - 

Medipol Bahçelievler

2021 - 2022

MEDIPOL UNIVERSITY SEFAKÖY HOSPITAL

2018 - 2020

İSTİNYE UNIVERSITY FACULTY OF MEDICINE

2014 - 2020

TOKAT STATE HOSPITAL

2010 - 2010

BINGOL STATE HOSPITAL

Education:

2021

MEDIPOL UNIVERSITY, GASTROTEROLOGY

2018

İSTINYE UNIVERSITY, INTERNAL DISEASES USA

2014

ANKARA TRAINING AND RESEARCH HOSPITAL, GASTROENTEROLOGY

2010

FIRAT UNIVERSITY, FACULTY OF MEDICINE/INTERNAL MEDICAL SCIENCES DEPARTMENT/INTERNAL MEDICINE DEPARTMENT

2004

FIRAT UNIVERSITY, FACULTY OF MEDICINE

A. International Peer-Reviewed Journal Articles:

Title: Fatal fulminant hepatitis B after withdrawal of entecavir treatment in a patient with HBeAg seroconversion.

• Authors: Sarıkaya Murat, Koçak Erdem, Köklü Seyfettin, Babalı Ayşegül, Çakal Başak
• Journal: Acta Gastro-Enterologica Belgica
• Year: 2012
• Volume/Issue: (Kontrol No: 1206043)

Title: Acute gastric obstruction resulting from gallstone-induced bezoar.

• Authors: Sarıkaya Murat, Koçak Erdem, Köklü Seyfettin, Akbal Erdem
• Journal: The American Surgeon
• Year: 2012
• Volume/Issue: 78(12)
• Page: 529
• (Kontrol No: 1129707)

Title: Garlic-induced esophagitis.

• Authors: Doğan Zeynal, Sarıkaya Murat, Filik Levent, Ergül Bilal
• Journal: Acta Gastro-Enterologica Belgica
• Year: 2013
• Volume/Issue: 76(2)
• Page: 262
• (Kontrol No: 1131422)

Title: Association between Helicobacter pylori and liver-to-spleen ratio.

• Authors: Doğan Zeynal, Sarıkaya Murat, Filik Levent, Ergül Bilal
• Journal: European Journal of Gastroenterology & Hepatology
• Year: 2013
• Volume/Issue: 25(1)
• Pages: 107-110
• Citations: 7
• DOI: 10.1097/MEG.0b013e3283590c10
• (Kontrol No: 1131424)

Title: Crohn's disease masked by median arcuate ligament syndrome.

• Authors: Bıyıkoğlu İbrahim, Sarıkaya Murat, Uysal Ramadan Selma, Ergül Bilal, Doğan Zeynal
• Journal: Chinese Medical Journal
• Year: 2013
• Volume/Issue: 126 (14)
• Page: 2798
• Citations: 1
• (Kontrol No: 1131477)

Title: Telaprevir and anemia: What we learned from the first three patients.

• Authors: Sarıkaya Murat, Doğan Zeynal, Ergül Bilal, Filik Levent
• Journal: Scandinavian Journal of Infectious Diseases
• Year: 2013
• Volume/Issue: 45(7)
• Page: 575-575
• Citations: 2
• DOI: 10.3109/00365548.2012.759271
• (Kontrol No: 1129738)

Title: Magnesium and parathyroid hormone levels of patients using different proton pump inhibitors.

• Authors: Sarıkaya Murat, Filik Levent, Ergul Bilal, Doğan Zeynal
• Journal: Gastroenterology Nursing
• Year: 2013
• Volume/Issue: 36 (2)
• Pages: 145-148
• DOI: 10.1097/SGA.0b013e31828d3753
• (Kontrol No: 1129715)

Title: Is topical pharyngeal anesthesia necessary in esophagogastroduodenoscopy in all unsedated patients?

• Authors: Ergül Bilal, Sarıkaya Murat, Doğan Zeynal, Filik Levent, Bıyıkoğlu İbrahim
• Journal: Digestive Endoscopy
• Year: 2013
• Volume/Issue: 25(1)
• Pages: 90-91
• Citations: 2
• DOI: 10.1111/j.1443-1661.2012.01383.x
• (Kontrol No: 1129879)

Title: Inpatient Care Of Hepatitis C: Applying The Four Pillars Model To The Hospital Setting.

• Authors: Sarıkaya Murat, Filik Levent, Doğan Zeynal, Ergül Bilal
• Journal: Gastroenterology Nursing
• Year: 2013
• Volume/Issue: 36(2)
• Pages: 141-144
• DOI: 10.1097/SGA.0b013e31828d33db
• (Kontrol No: 1129712)

Title: "The "Bouveret's Syndrome" Case Resolved Without Necrotic Changes."

• Authors: Bilal Ergül, Murat Sarıkaya, Zeynal Doğan, Sevda İdil, Tarkan Karakan, Abdullah Çetin Köseoğlu
• Journal: Case Reports in Gastrointestinal Medicine
• Year: 2013
• Volume/Issue: 2013
• Article ID: 725434
• DOI: 10.1155/2013/725434
• (Kontrol No: 1131423)

Title: Severe acute pancreatitis due to hypertriglyceridemia.

• Authors: Sarıkaya Murat, Doğan Zeynal, Ergül Bilal, Filik Levent, Bıyıkoğlu İbrahim
• Journal: Case Reports in Gastrointestinal Medicine
• Year: 2013
• Volume/Issue: 2013
• Article ID: 945902
• DOI: 10.1155/2013/945902
• (Kontrol No: 1131425)

Title: Gallstone Ileus Caused by Cholecystoenteric Fistula Demonstrated on Computed Tomography.

• Authors: Sarıkaya Murat, Doğan Zeynal, Ergül Bilal, Filik Levent, Sevda İdil
• Journal: Case Reports in Medicine
• Year: 2013
• Volume/Issue: 2013
• Article ID: 652960
• DOI: 10.1155/2013/652960
• (Kontrol No: 1131426)

Title: Intestinal Perforation Due to Ingested Chicken Bone Mimicking Crohn's Disease.

• Authors: Sarıkaya Murat, Doğan Zeynal, Ergül Bilal, Filik Levent
• Journal: Case Reports in Gastrointestinal Medicine
• Year: 2013
• Volume/Issue: 2013
• Article ID: 604820
• DOI: 10.1155/2013/604820
• (Kontrol No: 1131427)

Title: Acute pancreatitis induced by hypertriglyceridemia: A case-based review.

• Authors: Sarıkaya Murat, Doğan Zeynal, Ergül Bilal, Filik Levent
• Journal: Turkish Journal of Gastroenterology
• Year: 2013
• Volume/Issue: 24(3)
• Pages: 276-280
• DOI: 10.4318/tjg.2013.0565
• (Kontrol No: 1129727)

Title: An Unusual Complication of Endoscopic Retrograde Cholangiopancreatography: Severe Acute Pancreatitis Leading to Death.

• Authors: Sarıkaya Murat, Doğan Zeynal, Ergül Bilal, Filik Levent, Tarkan Karakan
• Journal: Case Reports in Gastrointestinal Medicine
• Year: 2013
• Volume/Issue: 2013
• Article ID: 658370
• DOI: 10.1155/2013/658370
• (Kontrol No: 1131475)

Title: A Rare Cause of Abdominal Pain: Mesenteric Panniculitis.

• Authors: Sarıkaya Murat, Doğan Zeynal, Ergül Bilal, Filik Levent
• Journal: Case Reports in Gastrointestinal Medicine
• Year: 2013
• Volume/Issue: 2013
• Article ID: 925259
• DOI: 10.1155/2013/925259
• (Kontrol No: 1131476)

B. Contributions to Scientific Conferences:

Title: Suicidal poisonings in Turkey: demographic and clinical aspects.

• Authors: Sarikaya M., Gunes A., Goksu E., Erdogan G., Ozen C., Kaya A.
• Conference: 30th European Congress of Clinical Toxicology (EAPCCT)
• Year: 2000
• Abstract ID: P44
• (Kontrol No: 1131478)

Title: A Rare Cause of Gastrointestinal Bleeding: Aortoenteric Fistula.

• Authors: Doğan Zeynal, Sarıkaya Murat, Filik Levent, Ergül Bilal
• Conference: World Congress of Gastroenterology
• Year: 2013
• Abstract ID: P1367
• (Kontrol No: 1131479)

シナン・カラアスラン博士は、乳がん、大腸がん、泌尿生殖器系がんの管理において最高の腫瘍医の一人です。

職務経験

• 2014年から — アナドル医療センターの腫瘍内科医
• 2012-2014 — メディカルパークホスピタルの腫瘍内科医
• 2011-2012 — コジャエリ・デリンセ教育研究病院の腫瘍内科医
• 2010-2011 — エルズルム地域教育研究病院の腫瘍内科医
• 2009-2010 — トルコ武装軍、ギュルハネ軍事医科大学での軍務中の腫瘍内科学の専門家
• 2006-2009 — チェラッパシャ医科大学腫瘍内科学科での腫瘍内科学フェロー
• 2003-2006 — バイランパシャ国立病院の内科専門医
• 1997-2003 — ハセキ教育研究病院の内科研修生兼内科専門医。

教育

• 1997 — イスタンブール大学イスタンブール医科大学 — 一般医学の学位
• 2002 — ハセキ研修病院 — 内科の専門
• 2009 — イスタンブール大学、チェラッパシャ医科大学 — 腫瘍内科の専門。

所属

• トルコ医学会
• トルコ腫瘍医学会
• トルコ肺がん学会。

Şeref Kömürcü教授は、ECFMGおよびESMO認定の医療および乳腺腫瘍学者であり、トルコを拠点に20年以上の実践経験を持っています。硬癌、乳癌、大腸癌、肺癌の治療を専門としています。

職歴

• 2016年から — アナドル医療センターでの医療腫瘍学専門家

学歴

• 1986年 — ギュルハネ軍医学校 — 一般医学の学位
• 1993年 — ギュルハネ軍医学校 — 内科専門
• 1993年 — ECFMG（米国）証明書取得
• 1996年 — ギュルハネ軍医学校 — 医療腫瘍学専門
• 1999年 — ESMO医療腫瘍学証明書取得（ヨーロッパ）。

教育活動

• 2011-2016年 — ギュルハネ軍医学校の医療腫瘍学部で教授
• 1999-2011年 — ギュルハネ軍医学校の医療腫瘍学部で准教授。

受賞

• 2003年 — GATA教育および教育の成功賞
• 2009年 — GATA卓越したサービス賞。

科学活動

癌管理に関する110を超える論文を書いています。

会員

• アメリカ臨床腫瘍学会
• ヨーロッパ医療腫瘍学会
• 多国籍癌支持療法協会
• トルコ腫瘍グループ
• トルコ医療腫瘍機構
• 肺癌機構
• 医療コミュニケーション機構
• 乳房疾患協会。

この医師は1998年にイスタンブール大学のÇapa医学部を卒業し、2002年にCerrahpaşa医学部で放射線診断学およびインターベンショナルラジオロジーの研修を修了しました。診断放射線学とテレラジオロジー、さらにインターベンショナルラジオロジーを専門としており、12の国内および1つの国際会議に参加し、多数の口頭および書面発表を行っています。この医師はHisar Intercontinental Hospital、Merzifon Air Hospital、Istanbul Emar Center、Haseki Training and Research Hospitalで職務を務めてきました。

Dr. Rahib Hasanov is a medical oncologist. He graduated from Istanbul University Cerrahpaşa Faculty of Medicine (1999–2005). He completed an internal medicine residency (2009–2013) and a medical oncology fellowship at Marmara University (2015–2018). He also completed an observership at Houston Methodist Hospital (2006–2007).

He focuses on personalized oncology. His treatments include immunotherapy, targeted therapy, and novel agents. His clinical interests include gastrointestinal, breast, lung, and genitourinary cancers.

He attends national and international conferences. He welcomes patients from Turkey, Azerbaijan, Montenegro, Georgia, Uzbekistan, the Middle East, Europe, and the United States.

Prof. Dr. Sezer Sağlam is a medical oncologist at Gayrettepe Florence Nightingale Hospital. He specializes in gastrointestinal and breast cancers. He has contributed to cancer care through research, especially with his study on the best timing for surgery after neoadjuvant therapy in rectal cancer. This work has influenced global treatment protocols.

Dr. Sağlam has led clinical trials in targeted therapies and precision medicine. His research on liver-transplanted patients with hepatocellular carcinoma was nominated for the 2024 International Best Researcher Award. He is a member of ASCO, ESMO, and ENET. Dr. Sağlam provides personalized and evidence-based oncology care.

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)